Cargando…

Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations

The objective of this study was to prepare a suitable formulation for dermal delivery of diflucortolone valerate (DFV) that would maintain the localization in skin layers without any penetration and to optimize efficiency of DFV. Drug-loaded lecithin/chitosan nanoparticles with high entrapment effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Özcan, İpek, Azizoğlu, Erkan, Şenyiğit, Taner, Özyazıcı, Mine, Özer, Özgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564463/
https://www.ncbi.nlm.nih.gov/pubmed/23390364
http://dx.doi.org/10.2147/IJN.S40519
_version_ 1782258318748680192
author Özcan, İpek
Azizoğlu, Erkan
Şenyiğit, Taner
Özyazıcı, Mine
Özer, Özgen
author_facet Özcan, İpek
Azizoğlu, Erkan
Şenyiğit, Taner
Özyazıcı, Mine
Özer, Özgen
author_sort Özcan, İpek
collection PubMed
description The objective of this study was to prepare a suitable formulation for dermal delivery of diflucortolone valerate (DFV) that would maintain the localization in skin layers without any penetration and to optimize efficiency of DFV. Drug-loaded lecithin/chitosan nanoparticles with high entrapment efficiency (86.8%), were successfully prepared by ionic interaction technique. Sustained release of DFV was achieved without any initial burst release. Nanoparticles were also incorporated into chitosan gel at different ratios for preparing a more suitable formulation for topical drug delivery with adequate viscosity. In ex-vivo permeation studies, nanoparticles increased the accumulation of DFV especially in the stratum corneum + epidermis of rat skin without any significant permeation. Retention of DFV from nanoparticle in chitosan gel formulation (0.01%) was twofold higher than commercial cream, although it contained ten times less DFV. Nanoparticles in gel formulations produced significantly higher edema inhibition in rats compared with commercial cream in in-vivo studies. Skin blanching assay using a chromameter showed vasoconstriction similar to that of the commercial product. There were no barrier function changes upon application of nanoparticles. In-vitro and in-vivo results demonstrated that lecithin/chitosan nanoparticles in chitosan gel may be a promising carrier for dermal delivery of DFV in various skin disorders.
format Online
Article
Text
id pubmed-3564463
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35644632013-02-06 Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations Özcan, İpek Azizoğlu, Erkan Şenyiğit, Taner Özyazıcı, Mine Özer, Özgen Int J Nanomedicine Original Research The objective of this study was to prepare a suitable formulation for dermal delivery of diflucortolone valerate (DFV) that would maintain the localization in skin layers without any penetration and to optimize efficiency of DFV. Drug-loaded lecithin/chitosan nanoparticles with high entrapment efficiency (86.8%), were successfully prepared by ionic interaction technique. Sustained release of DFV was achieved without any initial burst release. Nanoparticles were also incorporated into chitosan gel at different ratios for preparing a more suitable formulation for topical drug delivery with adequate viscosity. In ex-vivo permeation studies, nanoparticles increased the accumulation of DFV especially in the stratum corneum + epidermis of rat skin without any significant permeation. Retention of DFV from nanoparticle in chitosan gel formulation (0.01%) was twofold higher than commercial cream, although it contained ten times less DFV. Nanoparticles in gel formulations produced significantly higher edema inhibition in rats compared with commercial cream in in-vivo studies. Skin blanching assay using a chromameter showed vasoconstriction similar to that of the commercial product. There were no barrier function changes upon application of nanoparticles. In-vitro and in-vivo results demonstrated that lecithin/chitosan nanoparticles in chitosan gel may be a promising carrier for dermal delivery of DFV in various skin disorders. Dove Medical Press 2013 2013-01-30 /pmc/articles/PMC3564463/ /pubmed/23390364 http://dx.doi.org/10.2147/IJN.S40519 Text en © 2013 Özcan et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Özcan, İpek
Azizoğlu, Erkan
Şenyiğit, Taner
Özyazıcı, Mine
Özer, Özgen
Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
title Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
title_full Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
title_fullStr Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
title_full_unstemmed Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
title_short Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
title_sort enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564463/
https://www.ncbi.nlm.nih.gov/pubmed/23390364
http://dx.doi.org/10.2147/IJN.S40519
work_keys_str_mv AT ozcanipek enhanceddermaldeliveryofdiflucortolonevalerateusinglecithinchitosannanoparticlesinvitroandinvivoevaluations
AT azizogluerkan enhanceddermaldeliveryofdiflucortolonevalerateusinglecithinchitosannanoparticlesinvitroandinvivoevaluations
AT senyigittaner enhanceddermaldeliveryofdiflucortolonevalerateusinglecithinchitosannanoparticlesinvitroandinvivoevaluations
AT ozyazıcımine enhanceddermaldeliveryofdiflucortolonevalerateusinglecithinchitosannanoparticlesinvitroandinvivoevaluations
AT ozerozgen enhanceddermaldeliveryofdiflucortolonevalerateusinglecithinchitosannanoparticlesinvitroandinvivoevaluations